切换至 "中华医学电子期刊资源库"
高级检索
中华腔镜泌尿外科杂志(电子版)

中华腔镜泌尿外科杂志(电子版) ›› 2026, Vol. 20 ›› Issue (02) : 209 -215. doi: 10.3877/cma.j.issn.1674-3253.2026.02.014

综述

前列腺癌免疫治疗的研究进展
李俊杰1, 董培2, 姚成1, 刘泽3, 李勇1,†()   
  1. 1423000　湖南郴州，湘南学院临床学院
    2510060　广州，中山大学肿瘤防治中心泌尿外科
    3423000　湖南郴州，湘南学院护理学院
  • 收稿日期:2025-04-17 出版日期:2026-04-01
  • 通信作者: 李勇
  • 基金资助:
    湖南省教育厅科学研究基金(21A0527)

Advances in immunotherapy for prostate cancer

Junjie Li1, Pei Dong2, Cheng Yao1, Ze Liu3, Yong Li1,†()   

  1. 1School of Clinical medicine, Xiangnan University, Chenzhou 423000, China
    2Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
    3School of Nursing, Xiangnan University, Chenzhou 423000, China
  • Received:2025-04-17 Published:2026-04-01
  • Corresponding author: Yong Li
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李俊杰, 董培, 姚成, 刘泽, 李勇. 前列腺癌免疫治疗的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 209-215.

Junjie Li, Pei Dong, Cheng Yao, Ze Liu, Yong Li. Advances in immunotherapy for prostate cancer[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2026, 20(02): 209-215.

前列腺癌是男性最常见的恶性肿瘤之一，其发病率和死亡率均居高不下。近年来，免疫治疗作为一种新兴的治疗手段，在多种肿瘤的治疗中取得了显著的疗效，也在前列腺癌中得到广泛应用，但仍面临诸多挑战。本文总结了前列腺癌免疫治疗的主要方法和联合治疗策略，未来的研究需要进一步探索前列腺癌肿瘤微环境的机制，寻找更有效的生物标志物，优化联合治疗方案，实施个体化治疗，以提高免疫治疗的安全性和效果。

关键词: 前列腺癌, 免疫治疗, 免疫检查点抑制剂, 肿瘤疫苗, 肿瘤微环境

Prostate cancer remains one of the most prevalent malignant tumors in males, with persistently high incidence and mortality rates. In recent years, immunotherapy has emerged as a novel therapeutic approach, demonstrating remarkable efficacy in treating various malignancies and gaining widespread application in prostate cancer. However, it still faces numerous challenges. This review summarizes the primary immunotherapeutic strategies and combination approaches for prostate cancer. Current research emphasizes the necessity to further elucidate the mechanisms of the prostate cancer tumor microenvironment, identify more effective biomarkers, optimize combination regimens, and implement personalized treatment to enhance the safety and efficacy of immunotherapy.

Key words: Prostate cancer, Immunotherapy, Immune checkpoint inhibitors, Cancer vaccines, Tumor microenvironment
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]
Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023)[J]. J Urol, 2023, 209(6): 1082-1090. DOI: 10.1097/JU.0000000000003452.
[3]
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.
[4]
Haffner MC, Zwart W, Roudier MP, et al. Genomic and phenotypic heterogeneity in prostate cancer[J]. Nat Rev Urol, 2021, 18(2): 79-92. DOI: 10.1038/s41585-020-00400-w.
[5]
Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer[J]. Endocr Rev, 2021, 42(3): 354-373. DOI: 10.1210/endrev/bnab002.
[6]
Fontana F, Anselmi M, Limonta P. Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy[J]. Cancer Lett, 2022, 534: 215619. DOI: 10.1016/j.canlet.2022.215619.
[7]
胡帅文, 吕敦庆, 潘晓华. 前列腺癌ADT相关骨质疏松症的机制及防治进展[J]. 中国骨质疏松杂志, 2023, 29(2): 252-257, 267. DOI: 10.3969/j.issn.1006-7108.2023.02.019.
[8]
徐东波, 张斌, 康印东, 等. 应用阿帕他胺、阿比特龙及比卡鲁胺治疗mHSPC的临床疗效观察及分析[J]. 现代泌尿生殖肿瘤杂志, 2025, 17(6): 384-388. DOI: 10.3870/j.issn.1674-4624.2025.06.006.
[9]
朱孝仁,陈敏斌,姜鉴倬,等. 基于单细胞测序探究去势抵抗性前列腺癌肿瘤微环境及细胞间通讯相关信号分子[J]. 江苏大学学报(医学版), 2024, 34(6): 497-506. DOI: 10.13312/j.issn.1671-7783.y240003.
[10]
De Velasco MA, Kura Y, Fujita K, et al. Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer[J]. Int J Urol, 2024, 31(4): 307-324. DOI: 10.1111/iju.15378.
[11]
Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study[J]. J Clin Oncol, 2020, 38(5): 395-405. DOI: 10.1200/JCO.19.01638.
[12]
Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014, 15(7): 700-712. DOI: 10.1016/S1470-2045(14)70189-5.
[13]
Sharma P, Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial[J]. Cancer Cell, 2020, 38(4): 489-499.e3. DOI: 10.1016/j.ccell.2020.08.007.
[14]
Beer TM, Kwon ED, Drake CG, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer[J]. J Clin Oncol, 2017, 35(1): 40-47. DOI: 10.1200/JCO.2016.69.1584.
[15]
Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study[J]. Ann Oncol, 2018, 29(8): 1807-1813. DOI: 10.1093/annonc/mdy232.
[16]
He J, Wu J, Li Z, et al. Immunotherapy vaccines for prostate cancer treatment[J]. Cancer Med, 2024, 13(20): e70294. DOI: 10.1002/cam4.70294.
[17]
Shore ND, Antonarakis ES, Hafron J, et al. Cellular immunotherapy for prostate cancer: lessons learned from 15 Years of sipuleucel-T[J]. Prostate Cancer, 2025, 2025: 9766669. DOI: 10.1155/proc/9766669.
[18]
Sonpavde G, McMannis JD, Bai Y, et al. Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer[J]. Cancer Immunol Immunother, 2017, 66(10): 1345-1357. DOI: 10.1007/s00262-017-2027-6.
[19]
Lilleby W, Gaudernack G, Brunsvig PF, et al. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer[J]. Cancer Immunol Immunother, 2017, 66(7): 891-901. DOI: 10.1007/s00262-017-1994-y.
[20]
Heath EI, Thakur A, Chen W, et al. Race-related differences in sipuleucel-T response among men with metastatic castrate–resistant prostate cancer[J]. Cancer Res Commun, 2024, 4(7): 1715-1725. DOI: 10.1158/2767-9764.crc-24-0112.
[21]
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010, 363(5): 411-422. DOI: 10.1056/NEJMoa1001294.
[22]
Dendreon. Provenge treatment and early cancer treatment [DB/OL].

URL    
[23]
Dendreon. Immunotherapy with APC8015 (Sipuleucel-T, Provenge) for asymptomatic, metastatic, hormone-refractory prostate cancer [DB/OL].

URL    
[24]
Capuozzo M, Santorsola M, Ianniello M, et al. Innovative drug modalities for the treatment of advanced prostate cancer[J]. Diseases, 2024, 12(5): 87. DOI: 10.3390/diseases12050087.
[25]
Wang J, Zhou K, Zhu H, et al. Current status and progress of the development of prostate cancer vaccines[J]. J Cancer, 2023, 14(5): 835-842. DOI: 10.7150/jca.80803.
[26]
Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress[J]. Clin Pharmacol Ther, 2020, 107(1): 112-122. DOI: 10.1002/cpt.1674.
[27]
Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and opportunities[J]. Stem Cell Res Ther, 2021, 12(1): 81. DOI: 10.1186/s13287-020-02128-1.
[28]
Wang AX, Ong XJ, D'Souza C, et al. Combining chemotherapy with CAR-T cell therapy in treating solid tumors[J]. Front Immunol, 2023, 14: 1140541. DOI: 10.3389/fimmu.2023.1140541.
[29]
Codd AS, Kanaseki T, Torigo T, et al. Cancer stem cells as targets for immunotherapy[J]. Immunology, 2018, 153(3): 304-314. DOI: 10.1111/imm.12866.
[30]
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies[J]. Blood Cancer J, 2021, 11(4): 69. DOI: 10.1038/s41408-021-00459-7.
[31]
Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study[J]. Lancet, 2020, 395(10231): 1208-1216. DOI: 10.1016/S0140-6736(20)30314-7.
[32]
Perera MPJ, Thomas PB, Risbridger GP, et al. Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate cancer[J]. Cancers, 2022, 14(3): 503. DOI: 10.3390/cancers14030503.
[33]
Sayar E, Patel RA, Coleman IM, et al. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer[J]. JCI Insight, 2023, 8(7): e162907. DOI: 10.1172/jci.insight.162907.
[34]
Xu M, Evans L, Bizzaro CL, et al. STEAP1-4 (Six-transmembrane epithelial antigen of the prostate 1-4) and their clinical implications for prostate cancer[J]. Cancers, 2022, 14(16): 4034. DOI: 10.3390/cancers14164034.
[35]
Danila DC, Szmulewitz RZ, Vaishampayan U, et al. Phase I study of DSTP3086S, an antibody-drug conjugate targeting Six-transmembrane epithelial antigen of prostate 1, in metastatic castration-resistant prostate cancer[J]. J Clin Oncol, 2019, 37(36): 3518-3527. DOI: 10.1200/JCO.19.00646.
[36]
王宇, 于大鹏, 杨彬. 免疫联合治疗在前列腺癌中的研究进展[J]. 癌症进展, 2024, 22(3): 249-252, 273. DOI: 10.11877/j.issn.1672-1535.2024.22.03.04.
[37]
Guan X, Polesso F, Wang C, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy[J]. Nature, 2022, 606(7915): 791-796. DOI: 10.1038/s41586-022-04522-6.
[38]
Powles T, Yuen KC, Gillessen S, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial[J]. Nat Med, 2022, 28(1): 144-153. DOI: 10.1038/s41591-021-01600-6.
[39]
Sweeney CJ, Gillessen S, Rathkopf D, et al. Abstract CT014: IMbassador250: a phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)[J]. Cancer Res, 2020, 80(16_Supplement): CT014. DOI: 10.1158/1538-7445.am2020-ct014.
[40]
Yu EY, Fong P, Piulats JM, et al. Pd16-12 pembrolizumab plus enzalutamide in abiraterone-pretreated patients with metastatic castration-resistant prostate cancer [J]. J Urol, 2020, 203(Supplement 4): e368. DOI: 10.1097/ju.0000000000000859.012.
[41]
Higa J, Wilenius K, Savino S, et al. Real world experience with pembrolizumab in recurrent or advanced prostate cancer[J]. Clin Genitourin Cancer, 2020, 18(4): e397-e401. DOI: 10.1016/j.clgc.2019.12.009.
[42]
Napoletano C, Ruscito I, Bellati F, et al. Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector T cell subsets[J]. J Clin Med, 2019, 8(3): 380. DOI: 10.3390/jcm8030380.
[43]
Fizazi K, Drake CG, Shaffer DR, et al. An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD)[J]. J Clin Oncol, 2018, 36(15_suppl): TPS3126. DOI: 10.1200/jco.2018.36.15_suppl.tps3126.
[44]
Kolinsky MP, Gravis G, Mourey L, et al. KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)[J]. J Clin Oncol, 2020, 38(6_suppl): 103. DOI: 10.1200/jco.2020.38.6_suppl.103.
[45]
Petrylak DP, Ratta R, Matsubara N, et al. Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study[J]. J Clin Oncol, 2023, 41(6_suppl): 19. DOI: 10.1200/jco.2023.41.6_suppl.19.
[46]
Fizazi K, González Mella P, Castellano D, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial[J]. Eur J Cancer, 2022, 160: 61-71. DOI: 10.1016/j.ejca.2021.09.043.
[47]
Graff JN, Liang LW, Kim J, et al. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer[J]. Future Oncol, 2021, 17(23): 3017-3026. DOI: 10.2217/fon-2020-1008.
[48]
Petrylak DP, Loriot Y, Shaffer DR, et al. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study[J]. Clin Cancer Res, 2021, 27(12): 3360-3369. DOI: 10.1158/1078-0432.CCR-20-1981.
[49]
Hu C, Liu J, Cheng F, et al. Amplifying mRNA vaccines: potential versatile magicians for oncotherapy[J]. Front Immunol, 2023, 14: 1261243. DOI: 10.3389/fimmu.2023.1261243.
[50]
Sinha M, Zhang L, Subudhi S, et al. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer[J]. J Immunother Cancer, 2021, 9(5): e002254. DOI: 10.1136/jitc-2020-002254.
[51]
Jiang Z, Xu Y, Du G, et al. Emerging advances in delivery systems for mRNA cancer vaccines[J]. J Control Release, 2024, 370: 287-301. DOI: 10.1016/j.jconrel.2024.04.039.
[52]
Nallasamy P, Nimmakayala RK, Parte S, et al. Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis[J]. Mol Cancer, 2022, 21(1): 225. DOI: 10.1186/s12943-022-01682-x.
[53]
Scott EN, Gocher AM, Workman CJ, et al. Regulatory T cells: barriers of immune infiltration into the tumor microenvironment[J]. Front Immunol, 2021, 12: 702726. DOI: 10.3389/fimmu.2021.702726.
[54]
Li C, Jiang P, Wei S, et al. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects[J]. Mol Cancer, 2020, 19(1): 116. DOI: 10.1186/s12943-020-01234-1.
[55]
Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?[J]. Cancer Sci, 2019, 110(7): 2080-2089. DOI: 10.1111/cas.14069.
[56]
Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity[J]. Nat Rev Immunol, 2021, 21(8): 485-498. DOI: 10.1038/s41577-020-00490-y.
[57]
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer[J]. Am J Cancer Res, 2020, 10(3): 727-742.
[58]
Prinzing B, Krenciute G. Hypoxia-inducible CAR expression: an answer to the on-target/off-tumor dilemma?[J]. Cell Rep Med, 2021, 2(4): 100244. DOI: 10.1016/j.xcrm.2021.100244.
[59]
初子斌, 徐烨, 殷自强, 等. 前列腺癌生物标志物研究进展[J]. 生物工程学报, 2024, 40(11): 3951-3973. DOI: 10.13345/j.cjb.240283.
[60]
Mojsak D, Dębczyński M, Kuklińska B, et al. The many faces of immune checkpoint inhibitor-associated pneumonitis: 4 case reports[J]. Am J Case Rep, 2022, 23: e936420. DOI: 10.12659/AJCR.936420.
[61]
Pe'er D, Ogawa S, Elhanani O, et al. Tumor heterogeneity[J]. Cancer Cell, 2021, 39(8): 1015-1017. DOI: 10.1016/j.ccell.2021.07.009.
[62]
Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma[J]. BMC Pulm Med, 2021, 21(1): 148. DOI: 10.1186/s12890-021-01513-7.
[63]
吴佳慧, 崔洁, 杨文博, 等. PD-1/PD-L1抑制剂在前列腺癌免疫治疗中的研究进展[J]. 临床医学进展, 2023, 13(6): 10496-10504. DOI: 10.12677/ACM.2023.1361469.
[1] 栗家兴, 程紫轩, 吕欣悦, 王江芬, 张晶晶, 张亚芬. 肿瘤浸润淋巴细胞在乳腺癌免疫治疗中的作用及其预后预测价值[J/OL]. 中华乳腺病杂志(电子版), 2026, 20(01): 49-54.
[2] 杨轶, 廖新惠, 陈杰青, 吴建挺, 张仲富, 韩晓红, 梅红兵. 机器人辅助腹腔镜对比腹腔镜前列腺癌根治术：一项针对低、中危前列腺癌患者的回顾性研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(02): 197-201.
[3] 梅昊楠, 杨瑞, 刘修恒. 人工智能辅助病理学图像分析在前列腺癌诊断中的研究进展[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 1-7.
[4] 蒋钟吉, 郭洪, 王东文. 近红外显影技术在前列腺癌淋巴组织显影及病理评估中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 8-14.
[5] 李勇义, 赵均雄, 郭建东, 李文萱, 孟占鳌, 覃杰, 陈涵潇. 瘤体-瘤周细胞外容积模型对前列腺癌的诊断价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 56-64.
[6] 刘辉, 谢周洲, 周晓琪, 张桂豪, 江惠明, 陈南辉. 靶向SOAT1对前列腺癌的作用和机制研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 95-101.
[7] 覃桂林, 赵善超, 陈明坤. 人口老龄化背景下中国前列腺癌的疾病负担与筛查策略分析[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 102-107.
[8] 许鹏, 邓一鸣, 张兴超, 莫益鑫, 郑炯文, 陈春晓, 郭凯, 徐啊白. 广东省医学会泌尿外科疑难病例多学科会诊（第24期）——膀胱憩室癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2026, 20(01): 117-122.
[9] 高嘉钰, 张焕磊, 韩发彬. 单细胞测序在髓母细胞瘤微环境及转移复发研究中的应用[J/OL]. 中华细胞与干细胞杂志(电子版), 2026, 16(01): 31-38.
[10] 尹鹏飞, 吴堃, 王槐志, 蔡磊. 肝癌免疫治疗策略及其在围手术期中应用进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 21-27.
[11] 刘铁鑫, 王震侠. 肿瘤相关成纤维细胞在胰腺导管腺癌中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 124-131.
[12] 王春茂, 韩鸣, 王子彤. 局限期小细胞肺癌新辅助治疗后完全病理学缓解五例[J/OL]. 中华临床医师杂志(电子版), 2025, 19(07): 550-554.
[13] 陆飞, 邓朗朗, 刘江江, 张煜, 冯伟, 马海涛. 局部进展期食管鳞状细胞癌患者新辅助免疫联合化疗前后体成分变化与围手术期结局的相关性分析[J/OL]. 中华胸部外科电子杂志, 2026, 13(01): 36-48.
[14] 续文栋, 郑锴, 张鹏, 张华阳, 李润泽, 常东旭. 单免疫治疗晚期肺腺癌多发脑转移患者1例[J/OL]. 中华胸部外科电子杂志, 2026, 13(01): 83-87.
[15] 《中华胸部外科电子杂志》编辑部. 达芬奇菁英术者系列线上研讨会第二期：新辅助免疫治疗后机器人肺外科专题[J/OL]. 中华胸部外科电子杂志, 2026, 13(01): 91-94.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？